Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

NCT04293276 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT04293276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04293276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2020
Completion date
May 31, 2023
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer